| 40th week of 2008 patent applcation highlights part 54 |
| Patent application number | Title | Published |
|---|
| 20080241148 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2008-10-02 |
| 20080241149 | Antibodies to complementary peptides of thrombin or portions thereof - Disclosed are antibodies and antigen-binding fragments that bind to a complementary peptide having an amino acid sequence that is encoded by the complement of a nucleotide sequence encoding thrombin or a portion thereof. Such antibodies and antigen-binding fragments can be agonists or antagonists of thrombin receptor-mediated events. Also disclosed are methods of using the agonist antibodies and antigen-binding fragments of the invention to activate the non-proteolytically activated thrombin receptor (NPAR) in a subject in need of such treatment. In addition, methods of using the antagonist antibodies and antigen-binding fragments of the invention to inhibit activation of the NPAR in a subject in need of such treatment are disclosed. | 2008-10-02 |
| 20080241150 | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 - The present invention relates to a LNR-HD domain of the Notch receptor and methods of use. The method for expression and structural determination of the LNR-HD domain is described. | 2008-10-02 |
| 20080241151 | Virulence genes, proteins, and their use - A series of genes from | 2008-10-02 |
| 20080241152 | Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 2008-10-02 |
| 20080241153 | Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 2008-10-02 |
| 20080241154 | Isolation, Identification and Characterization of tmst2, a Novel Member of the TNF-Receptor Supergene Family - Novel TNF receptor polypeptides are disclosed, along with polynucleotides encoding the polypeptides and uses thereof. | 2008-10-02 |
| 20080241155 | Death domain containing receptor 4 - The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity. | 2008-10-02 |
| 20080241156 | Inhibitors of hepatitis C virus - The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses. | 2008-10-02 |
| 20080241157 | Nerve cell growth modulators (amphibodies) - The present invention relates to a nerve cell growth modulator denoted an amphibody. The amphibody according to the invention is comprised of at least two components, wherein a first component is capable of binding to a target and suppressing, or essentially neutralising, a nerve cell growth inhibitory effect thereof; and a second component is capable of stimulating nerve cell growth and/or regeneration. In the most preferred embodiment, the present amphibody is a neuromodulator comprised of the above disclosed two components connected by a linker element. Amphibodies according to the invention are a useful means of molecular disguise of a non-permissive environment into a permissive, and outgrowth promotive and favorable one. The present invention also relates to genetic and chemical methods of preparation of an amphibody according to the invention as well as to various advantageous uses thereof. | 2008-10-02 |
| 20080241158 | Human taste-specific receptor TIR3 - The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC. | 2008-10-02 |
| 20080241159 | METHODS AND COMPOSITIONS FOR SELECTIVE MODULATION OF VASCULARIZATION - The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis. | 2008-10-02 |
| 20080241160 | Human Monoclonal Antibodies Against Human IL-4 - Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases. | 2008-10-02 |
| 20080241161 | REMEDY FOR MAMMARY CANCER - Provided is a remedy for cancer which remedy is specific to cancer tissue and has therapeutic effects on mammary cancer. The remedy is available by associating an antitumor substance with a human monoclonal antibody having amino acid sequences of SEQ. ID. NOS. 1, 2 and 3 of Sequence Listing in hypervariable regions of a heavy chain and amino acid sequences of SEQ. ID. NOS. 4, 5 and 6 of Sequence Listing in hypervariable regions of a light chain by attaching the antibody to a liposome having the antitumor substance encapsulated therein. | 2008-10-02 |
| 20080241162 | HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS DIRECTED AGAINST HCV E2 GLYCOPROTEIN AND ENDOWED WITH IN VITRO NEUTRALIZING ACTIVITY - The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines. | 2008-10-02 |
| 20080241163 | TWEAK BINDING ANTIBODIES - Anti-Tweak antibodies are described. | 2008-10-02 |
| 20080241164 | BMP-3 antibodies and related methods - The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth. | 2008-10-02 |
| 20080241165 | Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fiber formation and modulating cross-beta structure-mediated toxicity - The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures. In one embodiment, the invention discloses a method for modulating extracellular protein degradation and/or protein clearance comprising modulating cross-β(beta) structure formation (and/or cross-β structure-mediated activity) of the protein present in the circulation. | 2008-10-02 |
| 20080241166 | Ligands that bind a receptor - The invention relates to ligands, such as immunoglobulin single variable domains, that have binding specificity for a receptor. Preferably the receptor is a cell surface receptor and/or the ligand inhibits the activity of the receptor. | 2008-10-02 |
| 20080241167 | CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION - The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV. | 2008-10-02 |
| 20080241168 | Transmembrane protein amigo and uses thereof - The present invention provides methods and compositions relating to vertebrate AMIGO, AMIGO2, AMIGO3, collectively vertebrate AMIGO polypeptides, related nucleic acids, and polypeptide domains thereof having vertebrate AMIGO-specific structure and activity, and modulators of vertebrate AMIGO function. | 2008-10-02 |
| 20080241169 | IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY - A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization. | 2008-10-02 |
| 20080241170 | Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 2008-10-02 |
| 20080241171 | Stem Cell Populations and Methods of Use - Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDH | 2008-10-02 |
| 20080241172 | Mutated Cholinesterase Sequences, Corresponding Nucleic Acids And Their Uses - The present invention relates to the use of a peptide sequence to form oligomers, especially tetramers, of cholinesterases, said peptide sequence comprising: a peptide corresponding to SEQ ID NO: 4, wherein any one of amino acids of position 12 to position 19 of SEQ ID NO; 4 is replaced by a cysteine, any homologous sequence of said peptide, or any sequence derived from said peptide, or any fragment of one of the sequences defined above, on the condition that is possesses the property of forming oligomers of cholinesterases. | 2008-10-02 |
| 20080241173 | Nucleic acid encoding receptor type protein kinase - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 2008-10-02 |
| 20080241174 | Production And Therapeutic Uses Of Th1-Like Regulatory T Cells - A unique CD4 | 2008-10-02 |
| 20080241175 | Dendritic Cell Co-Stimulatory Molecules - A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity. | 2008-10-02 |
| 20080241176 | METHOD FOR RAPID GENERATION OF MATURE DENDRITIC CELLS - Novel methods of rapidly generating dendrtic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non-limiting example, the method includes contacting the dendritic cell precursor or the mature dendritic cell with an antigen. The methods are of use both in vitro and in vivo. | 2008-10-02 |
| 20080241177 | Idiotypic vaccine - The present invention relates to idiotypic vaccine compositions for use in inducing immunity to p53. The invention preferably relates to a vaccine composition comprising a pharmaceutically acceptable carrier and at least one peptide, wherein the at least one peptide is selected from the group consisting of X | 2008-10-02 |
| 20080241178 | NOVEL HUMAN GENE FUNCTIONALLY RELATED TO DYSLEXIA - The present invention describes a novel human gene, DYXC1, which is functionally related to dyslexia. DYXC1 gene encodes a 420-amino acid residue protein. DYXC1 is expressed in several tissues, including the brain, and is localized in the nucleus. In addition, four single nucleotide polymorphisms (SNPs) in DYXC1 mRNA have been characterized in this invention. The invention provides diagnostic methods and materials for analysing allelic variation in DYSC1 gene. This invention also provides polypeptides encoded by DYXC1 gene and antibodies binding to said polypeptides. | 2008-10-02 |
| 20080241179 | Structural proteins of fish pancreatic disease virus and uses thereof - The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences. | 2008-10-02 |
| 20080241180 | Liquid Vaccines For Multiple Meningococcal Serogroups - Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135. | 2008-10-02 |
| 20080241181 | Environmentally regulated genes of Streptococcus suis - The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a | 2008-10-02 |
| 20080241182 | MYCOBACTERIUM TUBERCULOSIS PERSISTANCE GENES - Compositions and methods for preventing | 2008-10-02 |
| 20080241183 | Process For The Preparation And Use Of A Bivalent Vaccine Against Morphine-Heroine Addiction - The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed. Furthermore, the present invention reveals the efficacy of these conjugate formulations for triggering a sustained immunoprotection against morphine and heroin addiction using an intravenous self-administration paradigm of these two opiate substances in the rodent. Finally, a discussion is also made on the potential future use of these immunoconjugates in active vaccination protocols for treating both morphine and heroin addiction in the humans. | 2008-10-02 |
| 20080241184 | CANINE INFLUENZA VACCINES - The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza. | 2008-10-02 |
| 20080241185 | IMPRINTED POLYMERIC MATERIALS FOR BINDING VARIOUS TARGETS SUCH AS VIRUSES - Imprinted polymeric materials that selectively bind to a template article. Various types of template articles may be targeted by the imprinted polymeric materials, including microorganisms (e.g., viruses or bacteria) or biologic macromolecules (e.g., proteins or DNA). The imprinted polymeric material may be formed by template-directed synthesis using monomer units that interact with the template article. The monomer units are used to form a polymer matrix around the template article. Subsequently, the template article is removed from the polymer matrix. Also disclosed are imprinted polymeric materials comprising a cross-linked polymer matrix, which comprises a polyampholyte polymer. The polymer matrix has a binding cavity capable of selectively binding to a template article. Also disclosed are various uses for such imprinted polymeric materials. | 2008-10-02 |
| 20080241186 | NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION - The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention. | 2008-10-02 |
| 20080241187 | STABILIZATION OF VIRAL COMPOSITIONS - This invention concerns stabilized virus compositions, preferably a herpesvirus which may be an attenuated or genetically modified herpes simplex virus or varicella zoster virus, and a method of stabilizing viruses and immunizing preparations by the addition of sugars, preferably glucose and amino acids, preferably lysine. | 2008-10-02 |
| 20080241188 | Turkey herpesvirus vectored recombinant containing avian influenza genes - The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection. | 2008-10-02 |
| 20080241189 | Sequential Delivery Of Immunogenic Molecules Via Adenovirus And Adeno-Associated Virus-Mediated Administrations - An immunogenic regimen is provided. The regimen involves sequential administration of a recombinant adenoviral vector and a recombinant adeno-associated viral vector, each of which delivers a heterologous expression cassette encoding the same immunogenic product, or a cross-reactive immunogenic product. Also provided are products containing the vectors for use in the regimen of the invention. | 2008-10-02 |
| 20080241190 | VACCINATION OF HORSES AGAINST LAWSONIA INTRACELLULARIS - The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose. | 2008-10-02 |
| 20080241191 | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies - Disclosed is a cell wall C-polysaccharide antigen of | 2008-10-02 |
| 20080241192 | Vaccination against multiple serotypes of pasteurella multocida - The present invention provides methods for inducing cross-protective immunity against virulent strains of | 2008-10-02 |
| 20080241193 | CANINE LEISHMANIA VACCINE - The present invention provides vectors that contain and express in vivo | 2008-10-02 |
| 20080241194 | COMPOSITIONS AND METHODS FOR PROTECTING ORGANS, TISSUE AND CELLS FROM IMMUNE SYSTEM-MEDIATED DAMAGE - This invention concerns novel compositions and methods for for the protection of organs and cells from damage caused by activated lymphocytes, NK-cells and NK-like cells, more particularly compositions and methods for the protection of vascular endothelial cells from immune system-mediated damage. | 2008-10-02 |
| 20080241195 | Optimal Polyvalent Vaccine for Cancer - This invention provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of : a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine. | 2008-10-02 |
| 20080241196 | Artificial invaplex - An artificial invasin complex is prepared from purified or recombinantly prepared invasins and gram negative bacteria lipopolysaccharides. Typically, IpaB is mixed with IpaC to form a IpaB:IpaC complex. This invasin protein complex is then mixed with the lipopolysaccharide to form an artificial invasin complex. Additional bioactive molecules can be incorporated into the complex during manufacture. This artificial invasin complex is similar in function to native Invaplex 24 or Invaplex 50. The artificial invasin complex has superior immunogenicity properties relative to the native complex and can be taylor made. Its method of preparation lends itself to scale up. The artificial invasin complex can facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex. | 2008-10-02 |
| 20080241197 | MINOCYCLINE DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080241198 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases - Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases. | 2008-10-02 |
| 20080241199 | "Micro-Patch" for Assessment of the Local Microvasculature and Microcirculatory Vasoreactivity - A method for interrogating the microcirculation of a subject for use in characterizing function in health and disease, monitor changes in microcirculation over time, and identify responses in microcirculation to potentially harmful or beneficial interventions. The method includes delivering a study agent to a study surface for trans-surface delivery to the microvasculature of the subject and monitoring the microvasculature of the subject in the area of the study surface. A system is also provided which includes a micro-patch for delivery of study agent to a study surface for trans-surface delivery to the microvasculature of the subject and a monitoring probe for monitoring the microvasculature of the subject in the area of the study surface. | 2008-10-02 |
| 20080241200 | Cosmetic skin care system - A skin care cosmetic system that includes components in unit doses. Each system includes a substrate that is formed into a patch or mask, or a garment having a volume, for example, a sock, glove, or a sleeve. The substrate is treated with a moisture-containing formulation. Other system components may be unit doses of finishing lotion or skin preparation formulations or devices. | 2008-10-02 |
| 20080241201 | SENSITIVE SKIN PERFUMES - The invention relates to a fragrance composition for use in cosmetic, toiletry, personal care and cleansing, household cleaning and laundry products which comprises two to ten well characterized fragrance materials having a cosmetic function, of which at least two are selected from: | 2008-10-02 |
| 20080241202 | Multifunctional Cosmetic Composition, Process For Preparing Said Cosmetic Composition and Cosmetic Product - The present invention relates to a cosmetic composition comprising:—a silicone system composed by at least one light silicone present in an amount ranging from 0.25% to 6.00% by weight, and one heavy silicone present in an amount ranging from 0.25% to 4.00% by weight, and—an emollient system composed by at least one component selected from cupuacu butter, murumuru butter and Shea butter in an amount ranging from 1.0% to 5.0% by weight,—a cosmetically acceptable carrier, all the amounts based on the total weight of the cosmetic composition. This multifunctional cosmetic composition has a rapid absorption, differentiated properties of softness and smoothness, intensive and prolonged moisturizing when applied to the skin and can be applied to the skin before, during and after the bath. Further, the present invention relates to a process for preparing said cosmetic composition and to a cosmetic product comprising said composition. | 2008-10-02 |
| 20080241203 | Antiadhesive Kit, Process for Producing the Same and Method of Adhesion Prevention - An adhesion preventive kit and a method of preventing adhesion are provided which have a preventive effect on adhesion in a surrounding part of an edge of an injured or deficient tissue in guided regeneration therapy for an injured tissue. Specifically, the adhesion preventive kit includes: (A) a first membrane of at least two layers having a biodegradable base layer and an adhesion preventive layer provided respectively at outermost surfaces thereof and a second membrane of at least one layer having an adhesion preventive layer provided at an outermost surface thereof, or (B) an adhesion preventive membrane including a biodegradable base layer and an adhesion preventive layer, which membrane has an outermost surface constituted of the adhesion preventive layer and has a tissue sandwiching part. | 2008-10-02 |
| 20080241204 | WETTING SOLUTION FOR WET WIPES FOR COSMETIC, PERSONAL HYGIENE, DERMATOLOGICAL AND/OR CLEANING PURPOSES - The present invention relates to a wetting solution for manufacturing wet wipes or other wet flexible materials, and to such wet wipes for cosmetic, body care, dermatological and/or cleaning purposes, such as cleaning wipes, facial cleaning wipes, make-up remover wipes, refreshment wipes, baby wipes, wet toilet paper or eyeglass cleaning wipes, wherein the preferably aqueous wetting solution contains at least one amino acid ester, preferably from the group of pyrrolidone carboxylic acid esters, as an emulsifier. The invention further relates to the use of such amino acid esters as emulsifiers in wetting solutions for manufacturing said wet tissues. | 2008-10-02 |
| 20080241205 | Insect Behaviour Modifying Compounds - The invention provides methods for controlling thrips populations using thrips-repelling and/or thrips-attracting agents. The invention also provides methods of preventing or minimising damage to plants by use of the same. | 2008-10-02 |
| 20080241206 | CALCIUM PHOSPHATE CEMENTS COMPRISING AUTOLOGOUS BONE - Aspects of the invention include methods for producing flowable compositions, e.g. pastes, that set into calcium phosphate containing products, where the products include autologous bone. Aspects of the invention further include compositions produced by the methods, as well as kits for preparing the same. The subject methods and compositions produced thereby find use in a variety of applications, including hard tissue repair applications. | 2008-10-02 |
| 20080241207 | Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 2008-10-02 |
| 20080241208 | Methods, Compositions and Devices For Promoting Anglogenesis - This disclosure is, at least in part, directed to compositions, devices, and methods of promote angiogenesis. | 2008-10-02 |
| 20080241209 | System and Method for Forming Bone, Ligament, and Bone-Ligament Constructs - A system and method for forming a bone construct include providing bone marrow stromal cells on a substrate without disposing the cells within an exogenous scaffold, and culturing the cells in vitro in osteogenic media such that the cells form a confluent monolayer and detach from the substrate to form a self-organized three-dimensional bone construct. A system and method for forming a ligament construct using fibrogenic media and a system and method for forming a functionally integrated bone-ligament construct are also provided. | 2008-10-02 |
| 20080241210 | WOUND HEALING AGENT AND COMPOSITION - The present invention relates to a wound-treating agent and to a composition for the treatment of wounds comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or of a polypeptide having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:2. | 2008-10-02 |
| 20080241211 | DEVICE WHICH ENHANCES THE BIOLOGICAL ACTIVITY OF LOCALLY APPLIED GROWTH FACTORS WITH PARTICULAR EMPHASIS ON THOSE USED FOR BONE REPAIR - This invention provides a novel medical appliance for repairing, regenerating, maintaining, and/or augmenting a bone. The medical appliance generally includes an osteoinductive agent, an osteoinductive enhancer, and a carrier matrix. Also disclosed are methods, compositions, kits, and bone matrix formulations for regenerating, maintaining, and/or augmenting a bone. Exemplary preferred osteoinductive agents include growth factors such as BMP and TGF-β. Exemplary preferred osteoinductive enhancers include phytoestrogens such as naringin. | 2008-10-02 |
| 20080241212 | Biodegradable, Polymer Coverings for Breast Implants - A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction. | 2008-10-02 |
| 20080241213 | METHOD OF PREPARATION OF BIOABSORBABLE POROUS REINFORCED TISSUE IMPLANTS AND IMPLANTS THEREOF - A biocompatible tissue implant. The tissue implant may be bioabsorbable, and is made from a biocompatible polymeric foam. The tissue implant also includes a biocompatible reinforcement member. The polymeric foam and the reinforcement member are soluble in a common solvent. | 2008-10-02 |
| 20080241214 | Hydrogel-metal assembly - A hydrogel-metal assembly is provided. An intervening polymer network is used to bond together a water-swollen hydrogel layer and a biocompatible surface-modified metallic layer. The hydrogel layer is a water-swollen hydrogel layer of at least two interpenetrating polymers. The surface of the biocompatible surface-modified metallic layer is surface-modified with an inorganic material. The intervening polymer network has been chemically grafted to the inorganic material of the biocompatible surface-modified metallic layer through bi-functional linker molecules. The intervening polymer network is further physically or chemically cross-linked with the polymers of the water-swollen hydrogel. The hydrogel-metal assembly can be adapted to form a medical device, medical implant, an artificial implant, an orthopedic implant, or at least as part of a joint. The hydrogel-metal assembly is attractive for use as such implants or devices due to its characteristics such as, for example, low coefficient of friction, impact-absorption capacity or strength, and/or biocompatibility. | 2008-10-02 |
| 20080241215 | LOCAL VASCULAR DELIVERY OF PROBUCOL ALONE OR IN COMBINATION WITH SIROLIMUS TO TREAT RESTENOSIS, VULNERABLE PLAQUE, AAA AND STROKE - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. | 2008-10-02 |
| 20080241216 | Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture - A preparation containing active and/or auxiliary substance(s) for the time- and/or dose-controllable release of said substances, comprising at least two layers ( | 2008-10-02 |
| 20080241217 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant. | 2008-10-02 |
| 20080241218 | Coated medical devices for abluminal drug delivery - The invention relates generally to an implantable medical device for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. In particular, the invention pertains to an implantable stent, such as an intravascular stent, having a coating comprising an inorganic or ceramic oxide, metal or inert carbon and a plurality of reservoirs in such material that contain a therapeutic agent. | 2008-10-02 |
| 20080241219 | EXTENDED THERAPEUTIC EFFECT OCULAR IMPLANT TREATMENTS - Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site. | 2008-10-02 |
| 20080241220 | EXTENDED THERAPEUTIC EFFECT OCULAR IMPLANT TREATMENTS - Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site. | 2008-10-02 |
| 20080241221 | EXTENDED THERAPEUTIC EFFECT OCULAR IMPLANT TREATMENTS - Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site. | 2008-10-02 |
| 20080241222 | EXTENDED THERAPEUTIC EFFECT OCULAR IMPLANT TREATMENTS - Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site. | 2008-10-02 |
| 20080241223 | EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS - Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer. | 2008-10-02 |
| 20080241224 | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions For Intraocular Use - Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient. | 2008-10-02 |
| 20080241225 | BASIC PROCESSES TO PREPARE ANTIMICROBIAL CONTACT LENSES - This invention relates to antimicrobial lenses containing metals and methods for their production. | 2008-10-02 |
| 20080241226 | Methods and Kits For Administering Probiotics - Methods for administering probiotics comprising the steps of: administering a loading dose of a loading probiotic for a loading time period; and administering a dose of a botanical and/or additional materials for the loading time period are disclosed. The methods also include administering a maintenance dose of a maintenance probiotic, and/or a botanical and/or an additional material for a maintenance time period. Also disclosed are kits for use in administering probiotics. | 2008-10-02 |
| 20080241227 | Composition for Treating Dehydration in Large Mammals - A re-hydration supplement composition particularly suitable to counteract dehydration stresses in mature bovine mammals in the form of a pelletized feed supplement is disclosed which includes relatively large fractions of carbohydrates including saccharides, cationic and anionic electrolytes and a minor amount of betaine osmolyte. A process for pelleting is also disclosed. | 2008-10-02 |
| 20080241228 | Polypeptide Films and Methods - Disclosed herein are polypeptide multilayer films comprising a hybrid polypeptide comprising a first polypeptide segment and a second segment, the two segments being covalently joined by one or more non-peptidic linkages. The first segment comprises a polypeptide having a magnitude of net charge per residue of greater than or equal to 0.4, and a length of greater than or equal to about 12 amino acid residues. The second segment comprises a polypeptide or another polyelectrolyte. | 2008-10-02 |
| 20080241229 | Preparation Method of an Anti-Microbial Wound Dressing and the Use Thereof - The present invention discloses a method for the preparation of an anti-microbial wound dressing comprises alkalizing chitosan fiber to obtain alkalized chitosan fiber which is then etherified with chloroacetic acid to produce carboxymethyl chitosan fiber. Said fiber is made into dressing by fiber opening, web formation and needling. Alternatively chitosan fiber can be made into chitosan non-woven fabric by non-woven technique first which is then carboxylmethylated. The fabric is then made into wound dressing by cutting, packaging and sterilizing. The present invention also discloses the uses of the anti-microbial wound dressing made according to said method. The dressing according to the present invention can be applied in surgical wound, burn, and other chronic wound. Said dressing, when covering wound, is able to prevent moisture losses in body fluid, provide a favorable moist environment necessary for wound healing and maintain a fluid-free, maceration-free, germ-free wound surface. Said dressing is antiphlogistic, hemostatic and antalgic and promotes wound healing. | 2008-10-02 |
| 20080241230 | Method of Treating Scar Tissue - A method of treating scar tissue by applying a composite sheet for delivering therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Microchannels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of about 0 to about 30 days. | 2008-10-02 |
| 20080241231 | TRANSDERMAL DELIVERY OF DEXAMETHASONE AND PROMETHAZINE - Relief or prophylaxis from nausea and/or emesis are provided by transdermal compositions comprising dexamethasone and promethazine. The transdermal compositions are in the form of transdermal solutions and/or suspensions, such as lotions, pastes, gels, ointments or transdermal patches. | 2008-10-02 |
| 20080241232 | Use of green porphyrins to treat neovasculature in the eye - Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions. | 2008-10-02 |
| 20080241233 | TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY - A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface. | 2008-10-02 |
| 20080241234 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof. | 2008-10-02 |
| 20080241235 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080241236 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080241237 | Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family - The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions. | 2008-10-02 |
| 20080241238 | Controlled Release Coated Tablets Having Prolonged Gastric Retention - The present invention relates to a tablet composed of a core and a coating; said core is formed by two or more layers, wherein at least one of them contains an active agent ( | 2008-10-02 |
| 20080241239 | Pharmaceutical Tablets Having a Separation Mark Positioned on the Side of Said Tablets - A pharmaceutical tablet having two segments, one of which is a top segment and the other of which is a bottom segment, said tablet having at least one side wherein said tablet is provided with a separation mark or marks. | 2008-10-02 |
| 20080241240 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS - The present invention relates to a chronotherapeutic combination pharmaceutical formulation, which is designed to control the release of each ingredient of the combined drug in a predetermined rate based on the principle of the so-called chronotherapy and xenobiotics, where drugs are administered to exhibit pharmacological activities at predetermined time intervals. The formulations of the present invention comprise a dihydropyridine, and a statin, as active ingredients. The formulations are structured and arranged such that the respective release rates of the above ingredients can be controlled, thereby reducing or preventing antagonistic effects and side effects resulting from the interaction of the above ingredients, while maintaining the synergistic effect, and providing easy medication. | 2008-10-02 |
| 20080241241 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 2008-10-02 |
| 20080241242 | Porous Polyelectrolyte Materials - The present invention relates to porous polyelectrolyte materials, particularly nanoporous polyelectrolyte materials and to methods of making such materials. In a preferred embodiment, the invention relates to nanoporous polyelectrolyte spheres. In a preferred form of the invention, the materials are manufactured with the use of mesoporous silica spheres as templates. The invention also relates to a method of manufacturing such materials, and in particular, to a method of manufacturing such materials by a layer-by-layer process. | 2008-10-02 |
| 20080241243 | Drug delivery device for providing local analgesia, local anesthesia or nerve blockade - The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration. | 2008-10-02 |
| 20080241244 | Preservation of bioactive materials by freeze dried foam - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 2008-10-02 |
| 20080241245 | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage - The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration. | 2008-10-02 |
| 20080241246 | Cell-based therapies for treating liver disease - The invention provides, in part, methods for treating liver disease in a subject in need thereof. The invention further provides methods for improving liver function in a subject in need thereof, such as a subject with an ischemic liver or a cirrhotic liver. In some aspects, the methods of treatment comprise the administration of AC133+ alone or in combination with other cell populations. | 2008-10-02 |
| 20080241247 | Compositions and Methods To Control the Growth Of Microorganisms In Aqueous Systems - Compositions and methods for killing, preventing, or inhibiting the growth of microorganisms in an aqueous system or other systems are provided. The compositions can include at least one first cross-linkable polymer, at least one second cross-linkable polymer, and at least one cross-linking agent, wherein the water solubilities of each cross-linking polymer are different, such as by 10% to 100%. The compositions can further include at least one biocidal component. The compositions can be formulated to slowly release the biocidal component and/or the cross-linkable polymer, or rapidly release the biocidal component and slowly release the cross-linkable polymer. The compositions can be used to control algae. | 2008-10-02 |
